This page in English
Laddar profil information

Om mig

Giuseppe Masucci: Anknuten forskare vid institutionen för onkologi-patologi. Docent och överläkare vid Onkologiska kliniken, Karolinska Universitetssjukhuset.

  • Född 1951,  specialist i onkologi.
  • Har läkarexamen från universitetet i Ferrara, Italien.
  • Är knuten till Radiumhemmet i Stockholm sedan 1979.
  • Medverkar i Socialstyrelsens Kunskapscentrum för strålningsmedicin vid katastrofer (KcRN) som är en beredskapsfunktion vid Centrum för strålningsmedicin.
  • Medlem i Socialstyrelsens medicinska expertgrupp för radiologiska och nukleära händelser (RN-MeG).

Forskningsbeskrivning

Giuseppe Masuccis forskning är inriktad på immunoterapi och därmed relaterade prognosfaktorer som kan utnyttjas för ”personaliserad” (individrelaterad) cancermedicin. Hans grupp har fastställt att patientens vävnadstyp (HLA-antigen) har stor betydelse för den som utvecklat en malign tumörsjukdom. Gruppen har på senare år särskilt fokuserat på frekvensen av HLA-A2-allelen i Skandinavien; denna genvariant är korrelerad med dödligheten i äggstocks- och prostatacancer.

Giuseppe Masucci utvecklar också kombinationsbehandlingar med så kallad stereotaktisk ablativ radioterapi (SABR), som ger höga välavgränsade stråldoser till små tumörer, följd av immunterapi

Publikationer

Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-γ and multiple toll-like receptor agonists
Lövgren T, Sarhan D, Truxová I, Choudhary B, Maas R, Melief J, et al
Cancer immunology, immunotherapy : CII 2017;66(10):1333-1344

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
De Coaña Yp, Wolodarski M, Poschke I, Yoshimoto Y, Yang Y, Nyström M, et al
Oncotarget 2017;8(13):21539-21553

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma
Helgadottir H, Kis L, Ljungman P, Larkin J, Kefford R, Ascierto Pa, et al
Annals of oncology : official journal of the European Society for Medical Oncology 2017;28(7):1672-1673

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
Petrella Tm, Robert C, Richtig E, Miller Wh, Masucci Gv, Walpole E, et al
European journal of cancer (Oxford, England : 1990) 2017;86():115-124

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy
Masucci Gv, Cesano A, Eggermont A, Fox Ba, Wang E, Marincola Fm, et al
Journal of translational medicine 2017;15(1):223-

World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016
Galon J, Lugli A, Bifulco C, Pages F, Masucci G, Marincola Fm, et al
Journal of translational medicine 2017;15(1):212-

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino L, Botti G, Lorigan P, Masucci Gv, Hipp Jd, Horak Ce, et al
Drugs 2016;76(9):925-45

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015
Ascierto Pa, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies Ma, et al
Journal of translational medicine 2016;14(1):313-

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
Galon J, Fox Ba, Bifulco Cb, Masucci G, Rau T, Botti G, et al
Journal of translational medicine 2016;14():273-

Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis
Andersson E, Poschke I, Villabona L, Carlson Jw, Lundqvist A, Kiessling R, et al
ONCOIMMUNOLOGY 2016;5(1):e1052213-

Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations
Dobbin Kk, Cesano A, Alvarez J, Hawtin R, Janetzki S, Kirsch I, et al
Journal for immunotherapy of cancer 2016;4():77-

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation
Masucci Gv, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, et al
Journal for immunotherapy of cancer 2016;4():76-

Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome
Koelzer Vh, Dawson H, Andersson E, Karamitopoulou E, Masucci Gv, Lugli A, et al
Translational research : the journal of laboratory and clinical medicine 2015;166(2):207-17

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014
Ascierto Pa, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, et al
Journal of translational medicine 2015;13():374-

PD-L1 expression as a potential predictive biomarker
Fusi A, Festino L, Botti G, Masucci G, Melero I, Lorigan P, et al
The Lancet. Oncology 2015;16(13):1285-7

A novel approach for HLA-A typing in formalin-fixed paraffin-embedded-derived DNA
Villabona L, Leon Rodriguez Da, Andersson Ek, Seliger B, Dalianis T, Masucci Gv
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2014;27(9):1296-305

A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma
Poschke I, Lövgren T, Adamson L, Nyström M, Andersson E, Hansson J, et al
Cancer immunology, immunotherapy : CII 2014;63(10):1061-71

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Ascierto Pa, Grimaldi Am, Anderson Ac, Bifulco C, Cochran A, Garbe C, et al
JOURNAL OF TRANSLATIONAL MEDICINE 2014;:277-

Genotyping of human leukocyte antigen (HLA) ancestral haplotypes as prognostic marker in cancer using PCR analysis
Villabona L, Andersson E, Marchesi M, Masucci Gv
Methods in molecular biology (Clifton, N.J.) 2014;1102():353-66

HLA-A*02 in relation to outcome in human papillomavirus positive tonsillar and base of tongue cancer
Tertipis N, Villabona L, Nordfors C, Näsman A, Ramqvist T, Vlastos A, et al
Anticancer research 2014;34(5):2369-75

Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy
Pico De Coaña Y, Masucci G, Hansson J, Kiessling R
Cancer immunology, immunotherapy : CII 2014;63(9):977-83

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours
Galon J, Mlecnik B, Bindea G, Angell Hk, Berger A, Lagorce C, et al
The Journal of pathology 2014;232(2):199-209

HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome
Näsman A, Andersson E, Marklund L, Tertipis N, Hammarstedt-nordenvall L, Attner P, et al
PloS one 2013;8(10):e77025-

HLA-dependent tumour development: a role for tumour associate macrophages?
Marchesi M, Andersson E, Villabona L, Seliger B, Lundqvist A, Kiessling R, et al
Journal of translational medicine 2013;11():247-

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production
Pico De Coaña Y, Poschke I, Gentilcore G, Mao Y, Nyström M, Hansson J, et al
Cancer immunology research 2013;1(3):158-62

Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid Derived Suppressor Cells as well as Their Arginase1 Production (vol 1, pg 158, 2013)
Coana Yp, Poschke I, Gentilcore G, Mao Y, Nystrom M, Hansson J, et al
CANCER IMMUNOLOGY RESEARCH 2013;1(6):438-438

Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms
Mao Y, Poschke I, Wennerberg E, Pico De Coaña Y, Egyhazi Brage S, Schultz I, et al
Cancer research 2013;73(13):3877-87

Cancer classification using the Immunoscore: a worldwide task force
Galon J, Pagès F, Marincola Fm, Angell Hk, Thurin M, Lugli A, et al
Journal of translational medicine 2012;10():205-

Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer
Andersson E, Villabona L, Bergfeldt K, Carlson Jw, Ferrone S, Kiessling R, et al
CANCER IMMUNOLOGY IMMUNOTHERAPY 2012;61(8):1243-53

Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines
Poschke I, Mao Y, Adamson L, Salazar-onfray F, Masucci G, Kiessling R
CANCER IMMUNOLOGY IMMUNOTHERAPY 2012;61(6):827-38

Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours
Masucci Gv, Wersall P, Kiessling R, Lundqvist A, Lewensohn R
JOURNAL OF TRANSLATIONAL MEDICINE 2012;:104-

Defining the critical hurdles in cancer immunotherapy
Fox Ba, Schendel Dj, Butterfield Lh, Aamdal S, Allison Jp, Ascierto Pa, et al
Journal of translational medicine 2011;9():214-

[Paradigmatic shift in oncology: individualized melanoma treatment]
Hansson J, Djureen-mårtenson E, Edvinsson F, Falkenius J, Friesland S, Masucci G, et al
Lakartidningen 2011;108(20):1092-3

Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas
Zohar S, Baldi I, Forni G, Merletti F, Masucci G, Gregori D
PHARMACEUTICAL STATISTICS 2011;10(3):218-26

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
Butterfield Lh, Palucka Ak, Britten Cm, Dhodapkar Mv, Hakansson L, Janetzki S, et al
CLINICAL CANCER RESEARCH 2011;17(10):3064-76

A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, et al
CANCER RESEARCH 2010;70(7):2604-12

Immature Immunosuppressive CD14(+)HLA-DR-/low Cells in Melanoma Patients Are Stat3(hi) and Overexpress CD80, CD83, and DC-Sign
Poschke I, Mougiakakos D, Hansson J, Masucci Gv, Kiessling R
CANCER RESEARCH 2010;70(11):4335-45

Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology
Tahara H, Sato M, Thurin M, Wang E, Butterfield Lh, Disis Ml, et al
JOURNAL OF TRANSLATIONAL MEDICINE 2009;:45-

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
Johansson Cc, Egyhazi S, Masucci G, Harlin H, Mougiakakos D, Poschke I, et al
CANCER IMMUNOLOGY IMMUNOTHERAPY 2009;58(7):1085-94

The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma
Helgadottir H, Andersson E, Villabona L, Kanter L, Van Der Zanden H, Haasnoot Gw, et al
CANCER IMMUNOLOGY IMMUNOTHERAPY 2009;58(10):1599-608

A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"
Butterfield Lh, Disis Ml, Fox Ba, Lee Pp, Khleif Sn, Thurin M, et al
JOURNAL OF TRANSLATIONAL MEDICINE 2008;:81-

Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer
Gamzatova Z, Villabona L, Van Der Zanden H, Haasnoot Gw, Andersson E, Kiessling R, et al
TISSUE ANTIGENS 2007;70(3):205-13

A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients
Hanson Mgv, Ozenci V, Carlsten Mcv, Glimelius Bl, Frodin Jea, Masucci G, et al
CANCER IMMUNOLOGY IMMUNOTHERAPY 2007;56(7):973-84

Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma
Masucci Gv, Mansson-brahme E, Ragnarsson-olding B, Nilsson B, Wagenius G, Hansson J
MELANOMA RESEARCH 2006;16(4):357-63

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity
Norell H, Carlsten M, Ohlum T, Malmberg Kj, Masucci G, Schedvins K, et al
CANCER RESEARCH 2006;66(12):6387-94

Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancer
Gamzatova Z, Villabona L, Dahlgren L, Dalianis T, Nillson B, Bergfeldt K, et al
GYNECOLOGIC ONCOLOGY 2006;103(1):145-50

Effects of human plasma proteins on maturation of monocyte-derived dendritic cells
Tobiasova-czetoova Z, Palmborg A, Lundqvist A, Karlsson G, Adamson L, Bartunkova J, et al
IMMUNOLOGY LETTERS 2005;100(2):113-9

High frequency of human leucocyte antigen (HLA) A2 reflects a poorer prognosis in a group of advanced ovarian cancer patients.
Bergfeldt K, Hising C, Gamzatova Z, Tholander B, Avall-lundqvist E, Van Der Zanden Hgm, et al
JOURNAL OF CLINICAL ONCOLOGY 2005;23(16):467S-467S

Human leucocyte antigen (HLA) A2 phenotype incidence in patients with advanced ovarian cancer as negative clinical prognostic factor.
Masucci Gv, Gamzatova Z, Villabona L, Dahgren L, Dalianis T, Avall-lundqvist E, et al
JOURNAL OF CLINICAL ONCOLOGY 2005;23(16):478S-478S

Human leukocyte antigen (HLA) a2 as a negative prognostic factor in ovarian cancer patients
Gamzatova Z, Villabona L, Dalianis T, Van Der Zanden H, Tholander B, Hising C, et al
EJC SUPPLEMENTS 2005;3(2):265-266

Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy - A multicenter open randomized phase III study
Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J, et al
MEDICAL ONCOLOGY 2005;22(3):247-56

Alternating temazolomide and low doses rIL-2 in patients with metastatic melanoma. An open non-randomized phase I/II study.
Masucci Gv, Djuren-martensson E, Hansson J, Mansson-brahme E, Ragnarsson-olding B, Wagenius G
JOURNAL OF CLINICAL ONCOLOGY 2004;22(14):720S-720S

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer
Pavlenko M, Roos Ak, Lundqvist A, Palmborg A, Miller Am, Ozenci V, et al
BRITISH JOURNAL OF CANCER 2004;91(4):688-94

Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates
De Petris L, Bergfeldt K, Hising C, Lundqvist A, Tholander B, Pisa P, et al
MEDICAL ONCOLOGY 2004;21(1):49-52

Development of a technology platform for large-scale clinical grade production of DC
Adamson L, Palmborg A, Svensson A, Lundqvist A, Hansson M, Kiessling R, et al
CYTOTHERAPY 2004;6(4):363-71

A short-term dietary supplementation of high doses of vitamin E increases T helper 1 cytokine production in patients with advanced colorectal cancer
Malmberg Kj, Lenkei R, Petersson M, Ohlum T, Ichihara F, Glimelius B, et al
CLINICAL CANCER RESEARCH 2002;8(6):1772-8

Dendritic cells highly quoted on immunotherapy stock market
Masucci G
MEDICAL ONCOLOGY 2002;19(4):195-6

GM-CSF at relatively high topic concentrations can significantly enhance the healing of surgically induced chronic wounds after radiotherapy
Fernberg Jo, Brosjo O, Friesland S, Masucci G
MEDICAL ONCOLOGY 2001;18(3):231-5

Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappa B activation
Malmberg Kj, Arulampalam V, Ichihara F, Petersson M, Seki K, Andersson T, et al
JOURNAL OF IMMUNOLOGY 2001;167(5):2595-601

Leakage around voice prosthesis in laryngectomees: Treatment with local GM-CSF
Margolin G, Masucci G, Kuylenstierna R, Bjorck G, Hertegard S, Karling J
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK 2001;23(11):1006-10

Cells and cytokines in immunotherapy and gene therapy of cancer
Pawelec G, Rees Rc, Kiessling R, Madrigal A, Dodi A, Baxevanis C, et al
CRITICAL REVIEWS IN ONCOGENESIS 1999;10(1-2):83-127

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
Marchand M, Van Baren N, Weynants P, Brichard V, Dreno B, Tessier Mh, et al
INTERNATIONAL JOURNAL OF CANCER 1999;80(2):219-30

Will modern cancer vaccines reach clinical practice?
Masucci G
MEDICAL ONCOLOGY 1999;16(1):13-6

Efficient harvest of in vivo IL-2-activated CD3+ lymphocytes for adoptive immunotherapy by selective leukapheresis (lymphocytapheresis)
Masucci G, Svensson A, Hansson M, Hansson J, Nakazawa T, Salazar F, et al
JOURNAL OF HEMATOTHERAPY 1997;6(3):253-60

Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells
Salazaronfray F, Nakazawa T, Chhajlani V, Petersson M, Karre K, Masucci G, et al
CANCER RESEARCH 1997;57(19):4348-55

Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity
Kono K, Salazaronfray F, Petersson M, Hansson J, Masucci G, Wasserman K, et al
EUROPEAN JOURNAL OF IMMUNOLOGY 1996;26(6):1308-13

New clinical applications of granulocyte-macrophage colony-stimulating factor
Masucci G
MEDICAL ONCOLOGY 1996;13(3):149-54

ANTIBODIES TO EPSTEIN-BARR-VIRUS IN RELATION TO CLINICAL CHARACTERISTICS OF UNTREATED PATIENTS WITH HODGKINS-DISEASE
Merk K, Lennette E, Holm G, Johansson B, Masucci G, Grimfors G, et al
CANCER RESEARCH THERAPY & CONTROL 1995;4(3):223-229

Visa alla publikationer